The purpose of this Children’s Oncology Group study is to evaluate the safety and effectiveness of cixutumumab in combination with temsirolimus in children with sarcomas that have returned despite prior therapy or have stopped responding to standard therapy. Cixutumumab is an investigational drug; temosirolimus is approved for use in adults with kidney cancer, but its use in children is considered investigational.
Cixutumuab inhibits a protein involved in cancer growth called type 1 insulin-like growth factor receptor. Temsirolimus blocks a protein called mTOR, an important regulator of tumor growth. Laboratory studies suggest that these two drugs work well together. Both drugs are given intravenously (by vein).